{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T08:59:08Z","timestamp":1648717148634},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,21]]},"DOI":"10.1093\/ajhp\/zxy055","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T15:19:14Z","timestamp":1550762354000},"page":"349-352","source":"Crossref","is-referenced-by-count":0,"title":["Delayed-onset effect of clofarabine in the treatment of an adult patient with acute myeloid leukemia"],"prefix":"10.1093","volume":"76","author":[{"given":"Robert","family":"Walchack","sequence":"first","affiliation":[{"name":"Department of Pharmacy, West Virginia University Medicine, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Cumpston","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, West Virginia University Medicine, Morgantown, WV"},{"name":"Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Vos","sequence":"additional","affiliation":[{"name":"Department of Pathology, West Virginia University, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham S","family":"Kanate","sequence":"additional","affiliation":[{"name":"Osborn Hematopoietic Malignancy and Transplantation Program, West Virginia University, Morgantown, WV"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"2019061104595132100_CIT0001","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1182\/blood-2003-03-0925","article-title":"Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia","volume":"102","author":"Kantarjian","year":"2003","journal-title":"Blood."},{"key":"2019061104595132100_CIT0002","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2013-04-496596","article-title":"Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival","volume":"122","author":"Burnett","year":"2013","journal-title":"Blood."},{"key":"2019061104595132100_CIT0003","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2011.37.9743","article-title":"Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I trial","volume":"30","author":"Faderl","year":"2012","journal-title":"J Clin Oncol."},{"key":"2019061104595132100_CIT0004","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1600-0609.2011.01703.x","article-title":"Cytoreductive treatment with clofarabine\/ara-C combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with high-risk, relapsed, or refractory acute myeloid leukemia and advanced myelodysplastic syndrome","volume":"88","author":"Buchholz","year":"2012","journal-title":"Eur J Haematol."},{"key":"2019061104595132100_CIT0005","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1002\/ajh.23308","article-title":"Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients","volume":"87","author":"Scappini","year":"2012","journal-title":"Am J Hematol."},{"key":"2019061104595132100_CIT0006","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2141.2011.08831.x","article-title":"Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia","volume":"155","author":"Becker","year":"2011","journal-title":"Br J Haematol."},{"key":"2019061104595132100_CIT0007","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V116.21.1061.1061","article-title":"Phase II study of the combination of clofarabine plus idarubicin and cytarabine (CIA) in patients with relapsed\/refractory acute myeloid leukemia (AML)","volume":"116","author":"Naqvi","year":"2010","journal-title":"Blood"},{"key":"2019061104595132100_CIT0008","doi-asserted-by":"crossref","first-page":"a964","DOI":"10.1182\/blood.V112.11.964.964","article-title":"Results of a randomized phase 2 study of clofarabine plus cytarabine (CA) vs clofarabine plus idarubicin (CI) vs clofarabine, idarubicin, plus cytarabine (CIA) as salvage therapy in acute myeloid leukemia (AML)","volume":"112","author":"Faderl","year":"2008","journal-title":"Blood."},{"key":"2019061104595132100_CIT0009","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2141.2011.08940.x","article-title":"Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107)","volume":"156","author":"Amadori","year":"2012","journal-title":"Br J Haematol."},{"key":"2019061104595132100_CIT0010","first-page":"3030","article-title":"Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine","volume":"56","author":"Xie","year":"1996","journal-title":"Cancer Res."},{"key":"2019061104595132100_CIT0011","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1046\/j.1365-2141.2001.02661.x","article-title":"Acute myeloid leukaemia in human immunodeficiency virus-infected adults: epidemiology, treatment feasibility and outcome","volume":"112","author":"Sutton","year":"2001","journal-title":"Br J Haematol."},{"key":"2019061104595132100_CIT0012","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/00002030-200204120-00006","article-title":"Acute myeloid leukemia in patients infected with HIV-1","volume":"16","author":"Aboulafia","year":"2002","journal-title":"AIDS."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/76\/6\/349\/28791513\/zxy055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T20:37:50Z","timestamp":1574023070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/76\/6\/349\/5354452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":12,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,21]]},"published-print":{"date-parts":[[2019,2,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxy055","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,15]]},"published":{"date-parts":[[2019,2,21]]}}}